Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
|Videos|July 15, 2016
Dr. Elizabeth Plimack on Nivolumab in Kidney Cancer
Author(s)Elizabeth Plimack, MD
Advertisement
Elizabeth Plimack, MD, Director of Genitourinary Clinical Research, Associate Professor, department of hematology/oncology, Fox Chase Cancer Center, discusses the role of nivolumab in kidney cancer.
We now have long-term follow-up data from patients that have been on nivolumab for four to five years, says Plimack. About one-third of patients are still alive at four years.
This long-term benefit occurred in patients regardless of their initial response to therapy and risk group.
Biomarker development is needed, and as well as research regarding adverse events and combination possibilities. A lot can still be learned regarding how nivolumab should be used in kidney cancer, says Plimack.
Advertisement
Related to this article
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
BI-1808 as a single agent and in combination with pembrolizumab elicited responses and was generally well tolerated in patients with CTCL.
Advertisement
Advertisement
Trending on OncLive
1
Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma
2
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
3
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
4
FDA Accepts NDA for Varegacestat in Desmoid Tumors
5